Run for fat loss
Retatrutide + KLOW
Fixed-ratio blendadvanced16 weeksA fat-loss block that pairs weekly retatrutide with the daily KLOW healing blend. The logic people give is that aggressive weight loss is catabolic and hard on skin, joints and gut, and KLOW is meant to offset that. Retatrutide does the fat loss; KLOW does nothing for it.
Also sold as Reta + KLOW, Triple-G + KLOW.
What the ratio costs you
4 of these 5 compounds come out of one vial.
You cannot dose them independently. Every draw moves all 4 together in a ratio fixed by whoever filled the vial, so the only way to raise the component you care about is to raise the others with it.
Cautions — 8 on record
Read before running any of this
- Retatrutide is investigational and NOT approved by any regulator. There is no label, no long-term safety data and no pharmacy-grade product.
- Contraindicated with personal or family history of medullary thyroid carcinoma or MEN2, and with a history of pancreatitis.
- Not for use in pregnancy. Stop well before trying to conceive.
- Retatrutide raises heart rate dose-dependently more than semaglutide or tirzepatide because of the glucagon arm. Track resting heart rate and blood pressure.
- Nausea and appetite loss can be severe enough that protein and total calories fall too far. Under-eating protein during rapid loss is how people lose muscle and hair on this stack - KLOW does not fix that, food does.
- Stacking five compounds at once means that if something goes wrong you have no idea which one did it. Get stable on retatrutide alone for several weeks before adding KLOW.
- GHK-Cu adds a daily copper load on top of an already reduced food intake. Watch copper and zinc if you run this for the full block.
- Do not run with an active malignancy.
The 0 fixed-ratio cautions are printed above, at the top of the page.
Components
What is in it, and when
| Compound | Dose | Frequency | Time | Notes | |
|---|---|---|---|---|---|
| Retatrutide | 2 mg1 mg–12 mg | Once a week1×/week | Any time | Start at 1-2 mg weekly and hold each step for 4 weeks before increasing. Phase 2 trials stepped 1 -> 4 -> 8 -> 12 mg. Most people never need the top of that range. Same injection day each week. | Calculator → |
| GHK-CuRatio-locked | 1.25 mg1 mg–2 mg | Once daily7×/week | Evening | From the KLOW vial - 62.5% of every draw. Dosed on a different day-part to the retatrutide shot. | Calculator → |
| BPC-157Ratio-locked | 250 mcg200 mcg–500 mcg | Once daily7×/week | Evening | From the KLOW vial. Fixed at one fifth of the GHK-Cu dose. | Calculator → |
| TB-500Ratio-locked | 250 mcg200 mcg–500 mcg | Once daily7×/week | Evening | From the KLOW vial. Well below a standalone TB-500 loading dose. | Calculator → |
| KPVRatio-locked | 250 mcg200 mcg–500 mcg | Once daily7×/week | Evening | From the KLOW vial. | Calculator → |
Doses are per administration, in the canonical unit. The second line under each dose is the range people run. For ratio-locked components the calculator link opens that compound on its own — a blend vial is one draw, so reconstitute against the vial total, not the component.
Delivered dose vs standalone dose
Where each component actually lands
Each bar is that compound’s own dose range from its monograph, with a marker where this protocol puts it. A marker outside the band means the protocol is not dosing that compound the way it is dosed on its own — for a fixed-ratio vial that is arithmetic, not a choice.
Retatrutide
Within standalone range- Per dose
- 50% of typical
- Per week
- 2 mg · 50% of standalone
- Cycle total
- 32 mg · 16 doses
Start at 1-2 mg weekly and hold each step for 4 weeks before increasing. Phase 2 trials stepped 1 -> 4 -> 8 -> 12 mg. Most people never need the top of that range. Same injection day each week.
GHK-Cu
Ratio-lockedWithin standalone range- Per dose
- 83% of typical
- Per week
- 8.75 mg · 83% of standalone
- Cycle total
- 140 mg · 112 doses
From the KLOW vial - 62.5% of every draw. Dosed on a different day-part to the retatrutide shot.
BPC-157
Ratio-lockedWithin standalone range- Per dose
- 100% of typical
- Per week
- 1.75 mg · 100% of standalone
- Cycle total
- 28 mg · 112 doses
From the KLOW vial. Fixed at one fifth of the GHK-Cu dose.
TB-500
Ratio-lockedWithin standalone range- Per dose
- 83% of typical
- Per week
- 1.75 mg · 83% of standalone
- Cycle total
- 28 mg · 112 doses
From the KLOW vial. Well below a standalone TB-500 loading dose.
KPV
Ratio-lockedWithin standalone range- Per dose
- 50% of typical
- Per week
- 1.75 mg · 50% of standalone
- Cycle total
- 28 mg · 112 doses
From the KLOW vial.
Schedule — 16 weeks
Week by week
| Compound | 1Week 1 | 2Week 2 | 3Week 3 | 4Week 4 | 5Week 5 | 6Week 6 | 7Week 7 | 8Week 8 | 9Week 9 | 10Week 10 | 11Week 11 | 12Week 12 | 13Week 13 | 14Week 14 | 15Week 15 | 16Week 16 | Cycle total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Retatrutide2 mg · 1×/wk | 32 mg16 doses | ||||||||||||||||
| GHK-Cu1.25 mg · 7×/wk | 140 mg112 doses | ||||||||||||||||
| BPC-157250 mcg · 7×/wk | 28 mg112 doses | ||||||||||||||||
| TB-500250 mcg · 7×/wk | 28 mg112 doses | ||||||||||||||||
| KPV250 mcg · 7×/wk | 28 mg112 doses |
This protocol outlasts some of its own components
- GHK-Cu is typically cycled for 4 weeks; this protocol runs 16 weeks, so weeks 5–16 are past that. In a fixed-ratio vial you cannot drop it early without dropping everything else with it.
- BPC-157 is typically cycled for 8 weeks; this protocol runs 16 weeks, so weeks 9–16 are past that. In a fixed-ratio vial you cannot drop it early without dropping everything else with it.
- TB-500 is typically cycled for 6 weeks; this protocol runs 16 weeks, so weeks 7–16 are past that. In a fixed-ratio vial you cannot drop it early without dropping everything else with it.
- KPV is typically cycled for 8 weeks; this protocol runs 16 weeks, so weeks 9–16 are past that. In a fixed-ratio vial you cannot drop it early without dropping everything else with it.
Retatrutide — trial titration ladder
| Weeks | Step dose | Note |
|---|---|---|
| 1–2 | 500 mcg | starting dose |
| 3–4 | 1 mg | — |
| 5–8 | 2 mg | — |
| 9–12 | 4 mg | — |
| 13–16 | 8 mg | — |
This ladder is the escalation schedule recorded on the Retatrutide monograph, laid over this protocol’s 16 weeks. It is what the trials stepped through, not what this protocol prescribes — the schedule above holds the dose flat because that is all the protocol data says.
The dataset records one dose per component, so every dosing week is identical. Where a protocol note describes a loading phase followed by maintenance, that phase change is in the note, not in the schedule — read the component notes before assuming the grid is the whole story.
Evidence
What is actually known
Retatrutide has phase 2 randomized human data in obesity and type 2 diabetes with phase 3 ongoing. KLOW has none as a blend. There is no study of the combination and no evidence that KLOW preserves skin, hair or lean mass during GLP-1 driven weight loss - that claim is mechanistic hand-waving, not a finding. Treat the KLOW half as optional.
SourcesPubMedClinicalTrials.gov
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.